Market Size (2018)
$8.43B
Vertical: HealthcareBase Year: 2018
Market Size (2018)
$8.43B
Projected (2025)
$12.63B
CAGR (2016–2025)
6.0%
Key Players
10+
Advanced wound care is care given to serious non-healing wounds that require extra care. Some of the products used to treat such wounds include hydrogels, hydrocolloids, alginates, and film and foam dressings. These wound care treatments revolve around the principle of moisture therapy to the wound site to encourage natural cell repair.
Factors such as the increasing prevalence of diabetes & chronic wounds, rapidly growing aging population, and innovations in advanced wound therapy devices, are driving the growth of the advanced wound care market. Additionally, rising product launches by major market players are also driving the growth of the advanced wound care market. However, the rising number of market players leading to reducing the cost of wound dressings is posing as a challenge for the growth of the market.
The Advanced Wound Care Market market is projected to grow at a CAGR of 6.0% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansAdvanced Wound Care Market
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
The scope of the global advanced wound care market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on product type, application, end user, and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global advanced wound care market is characterized by the presence of many global, regional, and local vendors catering to the demand created by a large patient pool suffering from underlying conditions such as diabetic ulcers and vascular disease. The market is highly competitive, with players competing and collaborating to gain a substantial market share. Fragmented market, novel product launches, rising collaborative partnerships, and decisions undertaken to achieve operational efficiency are key factors that aid market growth. The manufacturers compete based on cost, quality, and reliability. It is decisive for the manufacturers to provide cost-efficient and innovative products to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, manufacturers should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional, and foreign players with small market shares also have a considerable presence. The international players may strengthen their presence worldwide through acquisitions and mergers during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new players with innovative products to enter into the market and increase the global market share.
The global advanced wound care market consists of a large number of global and local players operating in the respective regions. Although the market is fragmented with no clear leaders in the market, few players have captured significant market share in the global advanced wound care market.
With respect to the current scope of the report, 3M is observed to be the top player in the global advanced wound care market owing to its strong product portfolio and wide geographic presence. 3M held the 20% market share in the global market.
Smith & Nephew is the second major player with an 18% share, followed by Mölnlycke Health Care AB, which held a 13% share in the global advanced wound care market.
Threat of New Entrants
The threat of new entrants in the global advanced wound care market is medium. Any company trying to enter the market is required to accept the mandatory regulatory standards issued by government authorities. The market is also characterized by a high degree of brand loyalty, where establishing a brand name is difficult for newcomers. The rise in the demand for advanced wound care treatments owing to its potential growth in the coming future is expected to attract the currently established and other manufacturers to focus more on this segment. Furthermore, the cost involved in research and development (R&D) is comparatively high, which does not comfort the new entrants to enter the market easily.
Bargaining Power of Suppliers
The suppliers in the global advanced wound care market are raw material providers. There are various suppliers present in the global advanced wound care market. The switching cost of these suppliers is low due to intense competition. At present, there are many suppliers in the market owing to the high demand, increasing government support, and the availability of huge opportunities for the development of the market. The market is dominated by a few existing significant companies, and they hold the major share in the global market and have the capability to tolerate the fluctuating costs of advanced wound care products. Suppliers tend to enter into long-term associations, partnerships, and deals with the other product manufacturing companies, which leads to low to medium switching costs. Therefore, the overall bargaining power of suppliers in the global advanced wound care market is medium.
Threat of Substitutes
The threat of substitutes in the global advanced wound care market is low. There are very few substitutes available in the market, and buyer propensity to substitute is low. So, quality and trust issues backed by excellent service provided by existing players restrict the threat of substitutes.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global advanced wound care market. The number of buyers in the market is growing due to the increasing awareness about different products, along with the rising prevalence of chronic wounds. Additionally, the presence of healthcare providers and the number of players in the market is also increasing, which makes the bargaining power of buyers moderate due to the low switching costs.
Intensity of Rivalry
The degree of competition in the global advanced wound care market is high. Companies involved in the advanced wound care market are trying to introduce more advanced products for differentiating their product from rivals. Moreover, manufacturers also focus on the enhanced safety and quality of the products to increase the demand for these products in developed countries and developing regions.
Market estimates by geography (2025)
InsightAmericas leads with $4.81B by 2025, while Asia Pacific is projected to grow fastest at a 6.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $620.88M | $827.72M | $960.55M | 5.0% | 8% |
| Americas | $2.85B | $3.87B | $4.81B | 6.0% | 38% |
| Asia Pacific | $1.75B | $2.29B | $3.11B | 6.6% | 25% |
| Europe | $2.26B | $3.04B | $3.75B | 5.8% | 30% |
| Total | $7.47B | $10.03B | $12.63B | 6.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$12.63B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Foam Dressings | $2.67B | 6.6% | 25% |
| Film Dressings | $1.80B | 6.6% | 17% |
| Hydrocolloid Dressings | $1.44B | 4.9% | 13% |
| CHG Adhesive Dressings | $1.18B | 6.1% | 11% |
| Alginate Dressing | $1.03B | 6.2% | 10% |
| Surgical Tapes | $954.19M | 6.2% | 9% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Advanced Wound Care Market covering market dynamics, competitive landscape, and strategic outlook.
The Advanced Wound Care Market market is projected to reach $12.63B by 2025, growing at 6.0% CAGR. The Foam Dressings segment holds the largest share.
Advanced wound care is given to severe non-healing wounds that require extra care. Some of the products used to treat such wounds include hydrogels, hydrocolloids, alginates, and film and foam dressings. These wound care treatments revolve around the principle of moisture therapy to the wound site to encourage natural cell repair.
Prominent factors that drive the market growth are the increasing prevalence of diabetes & chronic wounds, rapidly growing aging population, and innovations in advanced wound therapy devices. However, the rising number of market players leading to reducing the cost of wound dressings is posing as a challenge for the growth of the market.
People with diabetes are more susceptible to wounds as their bodies have a slow healing process. According to Healthline, high blood sugar levels can negatively affect the immune system’s ability to operate efficiently, thereby slowing down the rate of wound healing.
Additionally, diabetes can also lead to poor blood circulation, which may further hamper the body’s ability to fight infections and healing procedures. The occurrence of diabetes and associated wounds has escalated in recent years, which led to an increase in the demand for effective wound care management for diabetic foot ulcers. According to the data by the Centers for Disease Control and Prevention in 2017, an estimated 30.3 million people in the US were diagnosed with diabetes. Moreover, according to the Food and Drug Administration (FDA), about 25% of people with diabetes would experience a foot ulcer in their lifetime. According to a research paper published in the National Center for Biotechnology Information (NCBI), in March 2017, the prevalence of diabetic foot ulcers was 6.3%, globally. The occurrence of chronic wounds and burns is increasing globally, which is likely to contribute to market growth. According to the report published in the National Center for Biotechnology Information (NCBI) in 2016, chronic wounds affected about 6.5 million people annually in the US. Moreover, as per the data by the World Health Organization (WHO), more than 1,000,000 people are moderately or severely burnt every year in India. Conclusively, the significantly growing incidence rate of diabetes and chronic wounds is anticipated to drive the growth of the market during the assessment period.
Hydrocolloid dressings promote a moist environment, which is optimal for wound healing. They also promote autolytic wound debridement by aiding in the removal of necrotic tissue, a barrier to wound healing. Additionally, they help in wound healing by retaining growth factors in the exudate, promoting granulation tissue formation.
However, the use of hydrocolloid dressings in treating diabetic foot ulcers remains a controversy. Hydrocolloid dressings are known to increase infection in the diabetes population as they retain bacteria and cause pus around the wound. Moreover, due to their occlusive nature, they can lead to an overly moist wound environment, with excess moisture causing dressing separation and peri-wound maceration. They also get dislodged if the wound produces heavy exudate, and upon removal, dressing residue may adhere to the wound bed and cause an odor.
These side-effects slow down the growth of hydrocolloid dressings, restraining the growth of the advanced wound care market.
Over the years, the advanced wound care market has witnessed many regional as well as local players. Players such as 3M, Convatec, Coloplast, Molnlycke, Scapa, Smith, and Nephew hold a significant share in the global advanced wound care market. However, there are many other players such as Axio Biosolutions, Organogenesis, Plastod S.p.A, and Abena A/S, among others that are operating in this market and have gained a significant share in the recent years. All these players are trying to expand their geographic presence, which will initiate cutthroat competition between competing companies to capture maximum market share in the emerging markets. To overcome the competition, companies are lowering the cost of their products, which is hampering the revenue of manufacturers.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 107 companies operating in the Advanced Wound Care Market market, including revenue, employee count, and market positioning where available.
Showing 107 of 107 companies
Mölnlycke Health Care AB
Company Headquarters: Sweden Founded: 1849 Workforce: 7,760 Company Working: Mölnlycke Health Care AB develops and manufactures single-use surgical and wound care products for customers, healthcare professionals, and patients internationally. It offers wound care systems, antiseptics, customized procedure trays, dermatology/scar treatment products, dental/stoma/tracheostomy, support/compression products, surgical drapes, surgical gloves, surgical staff clothing, wound care dressings, and wound care supplementary products for angiographic procedures, cardiovascular surgery, ear, nose and throat (ENT) surgery, and others.
Cardinal Health
Company Headquarters: Ohio, US Founded: 1971 Workforce: ~50,000 Company Working: Cardinal Health is a global, integrated healthcare services and products company. The firm provides customized solutions for hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physicians’ offices worldwide. It operates through two business segments, namely, medical products and pharmaceuticals. Through these segments, it offers cost-effective solutions that enhance the supply chain efficiency from hospital to home. It connects patients, providers, payers, pharmacists, and manufacturers for integrated care coordination and better patient management. Through its services and products, it serves nearly 85% of hospitals, more than 26,000 pharmacies, and more than 10,000 specialty physician offices and clinics across the US. In the fiscal year 2018, nearly 50,000 global employees operated in more than 46 countries.
Baxter International
Company Headquarters: Deerfield, Illinois, US Founded: 1931 Workforce: ~50,000 Company Working: Baxter International Inc. (Baxter) is a Fortune 500 American health care company with headquarters in Deerfield, Illinois, US. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions. Baxter is a leading producer of intravenous (IV) fluids and systems. It also manufactures infusion pumps, pre-filled syringes, biological sealants, and inhaled anesthetics, as well as dialyzers and other products for the treatment of end-stage renal disease. Its global footprint and critical nature of products and services play a key role in expanding access to healthcare in emerging and developed countries. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. As of December 31, 2018, Baxter manufactured products in over 20 countries and sold them in over 100 countries.
ConvaTec Inc.
Company Headquarters: Reading, UK Founded: 1978 Workforce: 10,000 Company Working: Convatec Inc produces and sells medical equipment. It offers products for advanced wound, ostomy, continence, and infusion treatment for acute-care hospitals and chronic-care facilities. Infusion care, advanced wound care, ostomy care, continence, and critical care, and are the four main business categories that the company concentrates on. The company's main products include urological catheters, skin care products, disposable infusion sets, wound dressings, diabetes, ulcers, multiple sclerosis, spina bifida, and other devices and accessories. The company's main products include urological catheters, skin care products, disposable infusion sets, wound dressings, diabetes, ulcers, multiple sclerosis, spina bifida, and other devices and accessories. Additionally, it provides products directly and via a network of distributors to hospitals, homecare agencies, pharmacies, insulin pump makers, and retail distributors in the homecare industry. The corporation also operates business throughout the Americas, Europe, Asia-Pacific, Middle East, and Africa.
Coloplast Corp.
Company Headquarters: Humlebaek, Denmark Founded: 1954 Workforce: ~11,000 Company Working: Coloplast Corp. (Coloplast) is a medical device company that develops and markets healthcare products and services across the world. The company functions through three operating segments, namely, chronic care, interventional urology, and wound and skin care. It provides medical devices for ostomy care, continence care products, wound care products, and products for the surgical treatment of urological and gynecological disorders. Coloplast markets and sells its products and services globally. Products are supplied to hospitals, institutions as well as wholesalers, distributors, and pharmacies. In selected markets, it is also a direct supplier to users. It has wholly-owned sales subsidiaries in its principal markets and employed about 12,000 people at the end of 2018.
Smith & Nephew
Company Headquarter: London, UK Founded: 1856 Workforce: 15000 employees Company Working: Smith & Nephew develops and markets medical devices worldwide. The company operates through four segments, namely, sports medicine, trauma, orthopedic reconstruction, and advanced wound management. The company primarily serves the providers of medical and surgical treatments and services. In 2014, Smith & Nephew acquired ArthroCare to broaden its sports medicine segment. The company has also acquired Healthpoint Biotherapeutics, which specializes in the production of bioactive for advanced wound management. Smith & Nephew has its presence in more than 100 countries and has major manufacturing units in the US, the UK, Switzerland, Germany, and China.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence